Category Archives: Biotechnology

For years, the international community has grappled with the threat of chemical, biological, radiological, and nuclear terrorism. And although al Qaeda and the Islamic State (ISIS) have demonstrated interest in and some capability to develop and use such weapons, there have been no successful mass casualty terrorist attacks involving them. Attempted attacks involving radiological dispersal devices or chemical and biological means have either failed or had a very limited impact. Experts such as John Parachini, Jeffrey Bale and Gary Ackerman, Adam Dolnik, and Rajesh Basrur and Mallika Joseph argue that the reason is terrorists inability to weaponize chemical, biological, radiological, or nuclear material. Others, including Brian Michael Jenkins, believe that the lack of mass causality attacks also has to do with self-restraint: perpetrators might not be able to control the consequences of such an attack. It could end up harming the members of the communities that the terrorists are purportedly fighting for and could therefore be counterproductive.

The recent WannaCry ransomware attack, however, could force the expert community to rethink such positions. Although available information suggests that North Korean hackers were behind these attacks, in which hackers took control of about 300,000 computers in over 150 countries and held the victims hostage in exchange for a payment of $300 in bitcoin, there is reason to believe that terrorist groups such as al Qaeda and ISIS could copy the tactic. In doing so, they would cause as much damage (loss of data and equipment) and chaos (in hospitals and other public utilities) as possible, comparable to the chaos and panic that could be caused by a chemical or biological attack.

Terrorists could use cyber capabilities to target any sector. But the most vulnerable industries are those with high proportions of old infrastructure onto which new technology has been grafted. According to a report from the U.S. Bureau of Economic Analysis, in 2015, the average age of all fixed assets in the United States stood at 22.8 years, with hospitals and utilities some of the worst culprits.

See more here:
Cyberterrorism and Biotechnology - Foreign Affairs (subscription)

Global Biotechnology Separation Systems market Report offers decisive insights into the overall Biotechnology Separation Systems industry along with the market dimensions and evaluation for the duration 2017 to 2022. The forenamed research study covers extensive analysis of various Biotechnology Separation Systems industry segments based on the type of applications, type of product Components and services, and different geographical regions.

At First, the research study provides exquisite knowledge of the global Biotechnology Separation Systems market structure, valuates and outlines its variable aspects & applications.

Further, Biotechnology Separation Systems market report along with computable information, qualitative information sets and evaluation tools are provided in this study for improved Biotechnology Separation Systems analysis of the overall market scenario and future prospects. Information such as Biotechnology Separation Systems industry predilection insights and drivers, challenges and fortuity assists the readers for understanding the current trends in the global Biotechnology Separation Systems market. Tools such as market positioning of Biotechnology Separation Systems key players and tempting investment scheme provide the readers with perception on the competitive scenario of the worldwide Biotechnology Separation Systems market. This Biotechnology Separation Systems report concludes with company profiles section that points out major data about the vital players involved in global Biotechnology Separation Systems industry.

Do Inquiry Before Accessing 2017-2022 Global Biotechnology Separation Systems Market Report at https://market.biz/report/global-biotechnology-separation-systems-market-gir/28805/#inquiry

In order to help key decision makers, the Biotechnology Separation Systems report also includes competitive depicting of the leading players in global Biotechnology Separation Systems market, tempting investment scheme market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Danaher Thermo Fisher Scientific BD Merck GE Healthcare Agilent Sysmex Alfa Wassermann Shimadzu Sartorius Stedim Biotech Illumina Waters Novasep 3M Purification Affymetrix Bio-Rad Laboratories Alfa Laval PerkinElmer Repligen Hitachi Koki

The industry research is disperse over the world which includes Biotechnology Separation Systems market in North America (USA, Canada and Mexico), Biotechnology Separation Systems market in Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Biotechnology Separation Systems market in Europe (Germany, France, UK, Russia and Italy), Biotechnology Separation Systems market in South America (Brazil, Argentina, Columbia etc.), Biotechnology Separation Systems market in Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) and Other parts of the Globe. Due to increasing job opportunities in Asia-Pacific countries, China and India will show a tremendous development in the global Biotechnology Separation Systems market. Use of advanced technology is holding the largest global Biotechnology Separation Systems market share in North America. Adoption of Biotechnology Separation Systems in the distinct fields in Europe will help to increase the expansion of Biotechnology Separation Systems market globally.

Commercial Scientific research

Membrane Filtration Chromatography Centrifuge Electrophoresis Flow Cytometry Others

Gain Full Access of Global Biotechnology Separation Systems Market Report with complete TOC at https://market.biz/report/global-biotechnology-separation-systems-market-gir/28805/

At last, Brief Description of Each Chapter is provided

Reports Consists 15 Chapters in it which thoroughly exhibit the global Biotechnology Separation Systems market 2017-2022.

Chapter 1, to features Biotechnology Separation Systems Introduction, product purview, market synopsis, market opportunities of Biotechnology Separation Systems, market peril, market motive;

Chapter 2, examines the top manufacturers in Biotechnology Separation Systems, with sales, revenue, and price of Biotechnology Separation Systems, in 2016 and 2017;

Chapter 3, exhibits the competitive situation among the Biotechnology Separation Systems top manufacturing players, with sales, revenue, and market share in 2016 and 2017;

Chapter 4, explores regionwise analysis of global Biotechnology Separation Systems market, with sales, revenue and market share, for each Biotechnology Separation Systems region, from 2012 to 2017;

Chapter 5, 6, 7, 8 and 9, scrutinizes the Biotechnology Separation Systems key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, displays the market based on Biotechnology Separation Systems type and application, with sales market share and Biotechnology Separation Systems growth rate by type, application, from 2012 to 2017;

Chapter 12, deals with Biotechnology Separation Systems market prognosis, by regions, type, and application, with Biotechnology Separation Systems sales and revenue, from 2017 to 2022;

Chapter 13, 14 and 15, explores Biotechnology Separation Systems industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source for Biotechnology Separation Systems.

The Industry study on global Biotechnology Separation Systems market encompasses full in-depth analysis of the parent market and provides important changes in Biotechnology Separation Systems dynamics. It also includes Former, on-going, and projected global Biotechnology Separation Systems market analysis in terms of volume and value.

The industry report on Biotechnology Separation Systemsserves comprehensive information about Segmentation details of the market in Biotechnology Separation Systems, Key strategies of major players, Market share analysis, and Biotechnology Separation Systems Emerging segments and regional markets.

Along with the Assessment of niche industry developments, global Biotechnology Separation Systems market report covers Testimonials to companies in order to fortify their foothold in the market.

Thus, the research study provides a comprehensive view of the global Biotechnology Separation Systems market, offering market dimensions and evaluations for the period from 2017 to 2022, keeping in mind the aforementioned factors.

Sumana Oza has been into market research industry for last 5 years. She has a keen interest and deep knowledge of research industry. She worked as an Research Analyst in GlobeMertix. Her goals in life are simple - to stay happy, healthy and to keep writing as long as she possibly can.

Read more from the original source:
Global Biotechnology Separation Systems Market 2017-2022: - People Exclusive

Prana Biotechnology Limited (PRAN) Earns News Impact Rating of 0.17 The Cerbat Gem Prana Biotechnology Limited logo Media headlines about Prana Biotechnology Limited (NASDAQ:PRAN) have trended somewhat positive this week, Alpha One reports. The research firm, a service of Accern, ranks the sentiment of press coverage by ... and more »

Originally posted here:
Prana Biotechnology Limited (PRAN) Earns News Impact Rating of 0.17 - The Cerbat Gem

The Cerbat Gem

Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst's Predictions StockNewsJournal Investors who are keeping close eye on the stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) established that the company was able to keep return on investment at -163.88 in the trailing twelve month while Reuters data showed that industry's average ... Puma Biotechnology Inc (PBYI) Upgraded at Cowen and CompanyThe Cerbat Gem Puma Biotechnology, Inc. (NasdaqGS:PBYI): Honing in on the TechnicalsGeneva Journal Puma Biotechnology Inc (PBYI) Given Average Rating of "Buy" by BrokeragesChaffey Breeze Sports Perspectives -The USA Commerce -Bibeypost.com -SEC.gov all 35 news articles »

Original post:
Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst's Predictions - StockNewsJournal

The Cerbat Gem

Aspen Investment Management Inc Buys 15 Shares of iShares NASDAQ Biotechnology Index (IBB) The Cerbat Gem iShares NASDAQ Biotechnology Index logo Aspen Investment Management Inc raised its stake in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 0.7% during the first quarter, according to its most recent Form 13F filing with the SEC. Baltimore Capital Management Inc. Invests $661000 in iShares NASDAQ Biotechnology Index (IBB)Chaffey Breeze Texas Yale Capital Corp. Continues to Hold Stake in iShares NASDAQ Biotechnology Index (IBB)BBNS Bbva Compass Bancshares Inc. Continues to Hold Stake in iShares NASDAQ Biotechnology Index (IBB)Markets Daily all 4 news articles »

Go here to see the original:
Aspen Investment Management Inc Buys 15 Shares of iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

TAIPEI, Taiwan, May 30, 2017 /PRNewswire/ --TaiGen Biotechnology Company, Limited ("TaiGen") today announced that it has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn (Nemonoxacin) to the China Food and Drug Administration (CFDA). Taigexyn is a novel non-fluorinated quinolone antibiotic.The NDA submission is supported by a pivotal Phase 3 trial comparing intravenous formulations of Taigexyn 500 mg to levofloxacin 500 mg in 518 patients with moderate to severe community-acquired pneumonia. The clinical success rates were 91.8% for Taigexyn vs. 85.7% for levofloxacin and Taigexyn was shown to be non-inferior to levofloxacin meeting the primary endpoint of the pivotal trial.

About Taigexyn Taigexyn is a novel broad spectrum antibiotic with excellent efficacy against drug-resistant bacteria available in both oral and intravenous formulations. The oral formulation is already approved for marketing and launched in Taiwan and mainland China. In addition, Taigexyn is also partnered in Russia, Commonwealth Independent States, Turkey, Mexico, Brazil and the Latin American territory for a total 32 countries worldwide.

More:
TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the ... - PR Newswire (press release)

FactsReporter

Puma Biotechnology (PBYI) Earns Media Sentiment Score of -0.01 The Cerbat Gem Puma Biotechnology logo News coverage about Puma Biotechnology (NYSE:PBYI) has been trending somewhat negative recently, AlphaOne Sentiment reports. AlphaOne, a unit of Accern, ranks the sentiment of news coverage by analyzing more than ... Brokerages Set Puma Biotechnology Inc (PBYI) Target Price at $68.42BBNS An Inside Look at the Technicals For Puma Biotechnology, Inc. (NasdaqGS:PBYI)Financial Newsweek Is Puma Biotechnology, Inc. (PBYI) a good buy?TopChronicle Transcript Daily -FactsReporter -Post Analyst -Zacks Investment Research all 86 news articles »

See the original post here:
Puma Biotechnology (PBYI) Earns Media Sentiment Score of -0.01 - The Cerbat Gem

Thanks to a $40,320 grant from the Ohio Department of Higher Education, some hard-working Lakeland Community College biotechnology students will be eligible for scholarships to cover their tuition and fees.

The program is called Choose Ohio First and is aimed at helping students pursuing degrees in science, technology, engineering, mathematics and medicine or STEMM, its associated web page shows.

In Lakelands case, the grant applies to biotechnology science students who meet certain criteria, a media release from the school confirms.

Students who receive this scholarship will have their tuition fully covered at Lakeland, said Joe Deak, chairman of the schools biotechnology science program.

Advertisement

He added that two Lakeland Community College students are now using this funding.

The scholarship covers up to $4,000 in tuition and fees for biotechnology students who dont receive PELL grants, according to Lakelands release.

It goes on to explain that high school graduates who passed chemistry with a C or better are encouraged to apply if they fit the following criteria:

Have an interest in a career in the laboratory biological sciences or data/analysis management as it pertains to biological data

Have a 3.0 overall GPA

Place into college algebra

Reside in Ohio.

Lakelands recent investments in its science and health technology programs and facilities have been making headlines in recent years, especially with the 2015 passage of its capital improvement bond issue, which is being used to fund a $40 million renovation and expansion of the colleges 20-year-old Health Technologies Building, bring the science hallway renovation to completion and help with other infrastructure improvements.

This is the stuff of the future, confirmed Arts & Sciences Division Dean Steven Oluic, who was on hand at a Sept. 1 open house for the renovated, third-floor science wing, when students, teachers, staff and anyone interested could see it, tour the classrooms and labs and learn about all the new, cutting-edge technology there.

I will submit to you that our biology, chemistry and physical science labs are among the best in the area, Oluic said. Really, youd be hard-pressed to find better labs.

College President Morris W. Beverage agreed.

When I went to Lakeland in 1972 and 1973, in the original labs up there, they were new, he said. This is the sort of thing you do every 40 or 50 years and you do it right. And, to do it right, you make sure the equipment and technology the students will be using are the standard of what theyll be using when they leave here. We want our students to experience what theyre going to experience in the world when they move on from here.

For Deak, theres no question thats exactly what Lakelands students are getting.

Deak said that, in his 20 years with the schools program, hes always been able to find grant money to keep it at the cutting edge and, thanks to this latest round of funding, the department is able to offer an unprecedented level of training to students who will likely go on to hit the ground running in roles which may not even exist yet.

Our folks wind up in research and development, quality control and medical lab technology, he said, just naming a few, and he added that the lab in which he answered these questions would pretty much be the envy of anyone at Case Western Reserve or Cleveland State University.

There are numbers to prove it, too.

According to Lakelands statement about the Choose Ohio First grant, Lakelands biotechnology science program has more than a 95 percent placement rate into jobs or transfer to a four-year school.

Institutions where graduates matriculate include Case Western Reserve University, Cleveland State University, Indiana Wesleyan University, John Carroll University, Lake Erie College and Youngstown State University, the statement reads. Lakeland also has a 2+2 articulation with Ursuline College, which allows students to transfer all of their credits and graduate with a bachelors degree in two additional years or less.

Deak said some students are even fortunate enough to land jobs with employers who actually pay their tuition for them.

After graduating from Lakeland, many students are then able to receive tuition waivers or reimbursements from their employers to reduce, or eliminate, the cost of the bachelors degree, he said.

More:
Lakeland Community College biotechnology sciences students getting boost from grant - News-Herald.com

By Robert Martin, InvestorPlace Writer|May 22, 2017, 11:12 am EDT

Puma Biotechnology Inc (NASDAQ:PBYI) jolted as much as 80% higher on Monday morning on news that theU.S. Food & Drug Administration posted a seemingly positive review of Pumas breast cancer drug, neratinib, ahead of an official vote Wednesday. PBYI then settled back to just 60% gains a few hours into the trading day.

The FDA asked a few questions and raised a few concerns, notably, tolerability of neratinib in this patient population is a concern given the frequent dose interruptions, reductions, and discontinuations observed, mostly due to diarrhea.

Specifically, 95% of patients in clinical trials suffered from diarrhea, with 40% of those suffering the grade 3 form of the side effect.

However, on the whole, PBYI investors seemed pleased with what the FDA did (and didnt) ask, taking the review as an encouraging sign ahead of the companys Oncologic Drugs Advisory Committee meeting, scheduled for Wednesday.

Neratinib (PB272) is being tested for the extended adjuvant treatment of HER2-positive early stage breast cancer. The drug is meant for patients who have already received Herceptin.

The FDA preview said that the primary analysis showed an improvement with neratinib, and that despite changes made to the clinical trial, the results of sensitivity analyses appear to be generally similar to the primary analysis results, supporting an effect of neratinib.

The results are receiving a warm welcome from PBYI stock longs, who have suffered a roughly 80% decline from 2014 highs even after todays boffo gains.

The company has been a hotbed of volatility thanks to its dependence on this single candidate Puma Biotechnology is pre-revenue, and has been incurring increasingly larger net losses over the past few years. Specifically, red ink of about $55 million in 2013 has ballooned to losses of $276 million last year.

As of this writing, Robert Martin did not hold a position in any of the aforementioned securities.

Article printed from InvestorPlace Media, http://investorplace.com/2017/05/puma-biotechnology-inc-pbyi-pops-60-fda-review/.

2017 InvestorPlace Media, LLC

More:
Puma Biotechnology Inc (PBYI) Pops 60% on FDA Review - Investorplace.com

Wednesday was a good day for stocks, and the Dow Jones Industrials and S&P 500 both climbed through milestone levels. Most market participants attributed the positive sentiment to the Federal Reserve, which released the minutes of its latest monetary policy meeting during the afternoon. The central bank revealed plans to clamp down on the size of its balance sheet, which it initially expanded in the aftermath of the financial crisis to provide liquidity to the bond market and additional stimulus to the U.S. economy. Investors were pleased that the Fed believes that it's no longer necessary to extend that level of monetary accommodation to the economy. In addition, some individual companies had extremely good news, and Abercrombie & Fitch (NYSE: ANF), Triumph Group (NYSE: TGI), and Puma Biotechnology (NASDAQ: PBYI) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Shares of Abercrombie & Fitch climbed 6% in the wake of reports that the teen retailer might receive an acquisition bid from a consortium of investors. According to The Wall Street Journal(subscription required), industry peer American Eagle Outfitters (NYSE: AEO) and private equity company Cerberus Capital Management are looking at putting together a potential buyout offer for Abercrombie & Fitch, following speculation that other players in the industry might also be interested in consolidation. A&F has been dealing with takeover speculation for a while, and it has typically noted that any discussions wouldn't necessary translate into actual offers. Yet with Abercrombie set to release its first-quarter financial results Thursday, investors will want to see signs that the company can take care of its challenges on its own -- or else they'll start clamoring more loudly for a buyout to take place.

Image source: Getty Images.

Triumph Group stock soared over 30% after the company announced its fiscal fourth-quarter financial results and resolved a dispute with aircraft manufacturer Bombardier. The aerospace components and systems specialist said that sales fell 13% from year-ago levels, and it posted a GAAP loss of $126.8 million. With challenges in its aerospace structures business, Triumph has focused on amending contracts and addressing operational and financial challenges, and the company's transformation plan has led to improving free cash flow and cost savings. Investors were also happy that Triumph reached a settlement of all of its disputes with Bombardier. Triumph said that the agreement "resets the commercial relationship between [Triumph] and Bombardier and allows each of them to better achieve their business objectives going forward."

Finally, shares of Puma Biotechnology jumped 30%. The biopharmaceutical company earned a hoped-for approval from the U.S. Food and Drug Administration advisory panel looking at its neratinib candidate treatment for breast cancer. The panel voted 12 to 4 in favor of recommending the drug to the FDA, and although panelists expressed some thoughts about potentially limiting the size of the group of women eligible to use the drug, investors nevertheless took the news as a positive. The FDA still needs to make its own decision about Puma's drug, and it isn't bound by the opinion of the advisory panel. Nevertheless, today's recommendation moves Puma one step further to getting a big win under its belt, and shareholders recognized that fact with the second big move in the stock this week.

Offer from The Motley Fool: The 10 best stocks to buy now

Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor, has tripled the S&P 500!*

Tom and David just revealed their ten top stock picks for investors to buy right now.

*Stock Advisor returns as of 5/1/2017.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Read the original post:
Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today - Madison.com